“`html
Unlocking the Mystery of Statin Side Effects: New Research Reveals How Muscle Problems Arise
Statins are a cornerstone of cardiovascular disease prevention, substantially reducing the risk of heart attacks and strokes for millions worldwide. However, a significant drawback of statin therapy is the incidence of muscle-related side effects, ranging from mild soreness to, rarely, severe muscle damage. Recent research from the University of British Columbia, in collaboration with the University of Wisconsin-Madison, has shed light on the molecular mechanisms behind thes adverse effects, paving the way for the advancement of safer statin medications. University of British Columbia News
How Statins Impact Muscle Cells: The Role of the Ryanodine Receptor
The research, published in nature Communications, focuses on the interaction between statins and the ryanodine receptor 1 (RyR1), a crucial protein found in muscle cells. Nature Communications RyR1 regulates calcium flow within muscle cells, controlling muscle contraction. Calcium is essential for muscle function,but an uncontrolled release can be toxic.
Using cryo-electron microscopy – a powerful imaging technique that allows scientists to visualize proteins at near-atomic resolution – researchers observed that statins bind to RyR1,causing the calcium channel to remain open longer than it should. This prolonged opening leads to a continuous leak of calcium into the muscle cell, ultimately causing damage and contributing to muscle pain, weakness, and, in rare cases, rhabdomyolysis (muscle breakdown that can lead to kidney failure).
The Unique Statin Binding Mechanism
The study specifically investigated atorvastatin, a commonly prescribed statin. However, researchers believe the underlying mechanism is likely applicable to other statins within the drug class. Their findings revealed a surprising and specific binding pattern:
- Initial Binding: One statin molecule initially binds to the RyR1 channel while it’s closed, preparing it to open.
- Clustering Effect: Two additional statin molecules then attach,effectively forcing the channel fully open.
- Unusual Clustering: This three-molecule clustering within a specific pocket of the protein had not been previously observed.
“This is the first time we’ve had a clear picture of how statins activate this channel,” explains Dr. Filip Van Petegem, a professor at UBC’s Life Sciences Institute. University of British Columbia News “It’s a big step forward as it gives us a roadmap for designing statins that don’t interact with muscle tissue.”
Toward Safer Cholesterol-Lowering Drugs
The identification of this specific binding mechanism offers a clear target for drug development. By modifying the statin molecule to eliminate the components responsible for interacting with RyR1, researchers aim to create statins that maintain their cholesterol-lowering efficacy while significantly reducing the risk
Keep reading